MCID: HYP006
MIFTS: 49

Hypertensive Heart Disease

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Hypertensive Heart Disease

MalaCards integrated aliases for Hypertensive Heart Disease:

Name: Hypertensive Heart Disease 12 54 15 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:11516
ICD9CM 34 402
NCIt 50 C157879
SNOMED-CT 67 155297007
ICD10 32 I11 I11.0 I11.9
UMLS 71 C0152105

Summaries for Hypertensive Heart Disease

Disease Ontology : 12 A heart disease that is caused by high blood pressure.

MalaCards based summary : Hypertensive Heart Disease is related to cardiovascular system disease and muscle hypertrophy. An important gene associated with Hypertensive Heart Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cytokine Signaling in Immune system and p70S6K Signaling. The drugs Spironolactone and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hypertensive heart disease includes a number of complications of high blood pressure that affect the... more...

Related Diseases for Hypertensive Heart Disease

Diseases related to Hypertensive Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 cardiovascular system disease 30.8 NR3C2 NPPB NPPA IGF1 CYP11B2 AGTR1
2 muscle hypertrophy 30.4 MSTN IGF1 FGF2
3 hypertensive retinopathy 30.2 NR3C2 AGTR1 ACE
4 renal dysplasia 30.2 AGTR1 AGT ACE
5 nephrosclerosis 30.2 NR3C2 CASP3 AGTR1 ACE
6 mitral valve insufficiency 30.2 NR3C2 NPPB NPPA ACE
7 sleep apnea 30.2 NPPB IGF1 AGT ACE
8 renovascular hypertension 30.2 NPPB NPPA AGTR1 ACE
9 mitral valve stenosis 30.2 NPPB NPPA ACE
10 aortic dissection 30.1 MMP9 MMP2 ACE
11 ischemia 30.0 NPPB FGF2 CASP3 ACE
12 renal hypertension 30.0 NR3C2 NPPB AGTR1 AGT ACE
13 first-degree atrioventricular block 29.9 NPPB ACE
14 arteriosclerosis 29.9 MMP9 FGF2 ANXA5 ACE
15 aortic valve insufficiency 29.9 NPPB NPPA ACE
16 pericardial effusion 29.9 NPPB NPPA FGF2 ACE
17 atrial fibrillation 29.9 NR3C2 NPPB NPPA AGTR1 AGT ACE
18 familial hypertension 29.9 NR3C2 NPPA CYP11B2 AGTR1 AGT
19 pulmonary edema 29.8 NPPB NPPA AGTR1 ACE
20 vascular disease 29.8 NPPB MMP9 IGF1 FGF2 CASP3 AGT
21 congestive heart failure 29.8 NR3C2 NPR1 NPPB NPPA CYP11B2 AGTR1
22 diastolic heart failure 29.8 NPPB NPPA MMP9 MMP2 MMP1 AGTR1
23 heart valve disease 29.8 NR3C2 NPPB NPPA CTF1 ACE
24 kidney disease 29.7 NR3C2 NPPB NPPA AGTR1 AGT ACE
25 malignant hypertension 29.7 NPPB NPPA AGTR1 AGT ACE
26 lipoprotein quantitative trait locus 29.4 NPPB NPPA MMP9 FGF2 CASP3 AGTR1
27 systolic heart failure 29.4 NR3C2 NPPB NPPA MMP9 MMP2 CYP11B2
28 polycystic kidney disease 29.3 MMP9 IGF1 FGF2 CASP3 AGTR1 AGT
29 hypertrophic cardiomyopathy 29.2 TPM1 NR3C2 NPPB NPPA MMP9 MMP2
30 stroke, ischemic 29.1 NPPB NPPA MMP9 CASP3 ANXA5 AGTR1
31 body mass index quantitative trait locus 11 28.9 NR3C2 NPR1 MSTN IGF1 AGT ACE
32 pulmonary hypertension 28.9 NPPB NPPA MMP9 IGF1 FGF2 CASP3
33 chronic kidney disease 28.9 NR3C2 NPPB NPPA MMP9 MMP2 IGF1
34 autosomal dominant polycystic kidney disease 28.8 NPPA MSTN IGF1 CYP11B2 CASP3 AGTR1
35 dilated cardiomyopathy 28.5 TPM1 TIMP2 NR3C2 NPPB NPPA MMP9
36 hypertension, essential 28.4 NR3C2 NPR1 NPPB NPPA MMP9 MMP2
37 heart disease 28.3 TPM1 TIMP2 NR3C2 NPPB NPPA MSTN
38 atrial standstill 1 10.6
39 extracranial arteriovenous malformation 10.4 MMP9 MMP2
40 focal myositis 10.4 MMP9 MMP2
41 aldosterone-producing adenoma 10.4 CYP11B2 AGTR1
42 fibrosis of extraocular muscles, congenital, 1 10.4
43 acute transverse myelitis 10.4 MMP9 MMP2
44 lentigo maligna melanoma 10.4 MMP9 MMP2
45 lateral myocardial infarction 10.4 NR3C2 ACE
46 nasal cavity squamous cell carcinoma 10.4 MMP9 MMP2
47 toxic myocarditis 10.4 NPPB ACE
48 chronic actinic dermatitis 10.4 MMP9 MMP1
49 fungal keratitis 10.4 TIMP2 MMP9
50 senile ectropion 10.4 MMP9 MMP2

Comorbidity relations with Hypertensive Heart Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Hypertensive Heart Disease:



Diseases related to Hypertensive Heart Disease

Symptoms & Phenotypes for Hypertensive Heart Disease

GenomeRNAi Phenotypes related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.6 TPM1
2 Decreased viability GR00055-A-2 9.6 TPM1
3 Decreased viability GR00055-A-3 9.6 TPM1
4 Decreased viability GR00240-S-1 9.6 CD36
5 Decreased viability GR00249-S 9.6 AGT CD36 FGF2 NPPA TPM1
6 Decreased viability GR00386-A-1 9.6 AGT CD36 FGF2 NPR1 NR3C2 TPM1
7 Decreased viability GR00402-S-2 9.6 CYP11B2 NPPA NPR1 TPM1

MGI Mouse Phenotypes related to Hypertensive Heart Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 ACE AGT AGTR1 CASP3 CD36 CYP11B2
2 homeostasis/metabolism MP:0005376 10.3 ACE AGT AGTR1 CASP3 CD36 CTF1
3 growth/size/body region MP:0005378 10.28 ACE AGT AGTR1 CASP3 CD36 CTF1
4 hematopoietic system MP:0005397 10.25 ACE AGTR1 ANXA5 CASP3 CD36 CYP11B2
5 immune system MP:0005387 10.17 ACE AGT AGTR1 ANXA5 CASP3 CD36
6 adipose tissue MP:0005375 10.08 ACE AGT AGTR1 CD36 CTF1 CYP11B2
7 muscle MP:0005369 10 AGT CASP3 CD36 FGF2 IGF1 MMP2
8 nervous system MP:0003631 9.77 ACE AGT AGTR1 CASP3 CD36 CTF1
9 neoplasm MP:0002006 9.7 ACE FGF2 IGF1 MMP1 MMP2 MMP9
10 renal/urinary system MP:0005367 9.36 ACE AGT AGTR1 CASP3 CD36 CYP11B2

Drugs & Therapeutics for Hypertensive Heart Disease

Drugs for Hypertensive Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
2
Amlodipine Approved Phase 3 88150-42-9 2162
3
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198
4
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
5
Hydrochlorothiazide Approved, Vet_approved Phase 3 58-93-5 3639
6 diuretics Phase 3
7 Hormone Antagonists Phase 3
8 Hormones Phase 3
9 Mineralocorticoid Receptor Antagonists Phase 3
10 Diuretics, Potassium Sparing Phase 3
11 Mineralocorticoids Phase 3
12 Angiotensin Receptor Antagonists Phase 3
13 Angiotensinogen Phase 3
14 Antihypertensive Agents Phase 3
15 Angiotensin II Type 1 Receptor Blockers Phase 3
16 LCZ 696 Phase 3
17 Giapreza Phase 3
18
Atropine Approved, Vet_approved 5908-99-6, 51-55-8 174174
19 Respiratory System Agents
20 Parasympatholytics
21 Anti-Asthmatic Agents
22 Neurotransmitter Agents
23 Cholinergic Antagonists
24 Anesthetics
25 Mydriatics
26 Cholinergic Agents
27 Muscarinic Antagonists
28 Bronchodilator Agents
29 Anti-Arrhythmia Agents

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease Completed NCT00865501 Phase 3 spironolactone;placebo
2 Role of ARNi in Ventricular Remodeling in Hypertensive LVH Recruiting NCT03553810 Phase 3 Entresto;Valsartan
3 E_Stethoscope : Portable Digital Auscultation Based on Wireless Sensor Node to Diagnose Diastolic Dysfunction in Hypertensive Heart Disease Unknown status NCT02809040
4 Asian American Partnerships in Research and Empowerment (AsPIRE) Completed NCT03100812
5 The Personalized Chinese Herb Formulas Are Evaluated for Their Effectiveness to Relieve Symptoms in Hypertensive Bradyarrhythmia Completed NCT04505228 Safflower (Carthamus Tinctorius) IgG4 | Serum | Allergy;Atropine Sulfate
6 Prevention of Cardiovascular Stiffening With Aging and Hypertensive Heart Disease Completed NCT03476785
7 Relationship Between Arteriosclerosis and Myocardial Work in Hypertensive Patients With Left Ventricular Ejection Fraction Retention Recruiting NCT04573257
8 Registro Campania Salute Network for the Treatment of Hypertension and Correlated Diseases Recruiting NCT02211365
9 Renal Sympathetic Denervation Restores Autonomic Imbalance and Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study Active, not recruiting NCT01990911 Medical therapy
10 EARLY Differentiation of MYOcardial Hypertrophy From Hypertensive Heart Disease: a Multi-center, Prospective, Controlled Clinical Trial Active, not recruiting NCT03271385
11 The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study Enrolling by invitation NCT04190420
12 Piloting the IPROACTIF Program to Preserve Functioning and Prevent Cognitive Decline Not yet recruiting NCT04682977

Search NIH Clinical Center for Hypertensive Heart Disease

Genetic Tests for Hypertensive Heart Disease

Anatomical Context for Hypertensive Heart Disease

MalaCards organs/tissues related to Hypertensive Heart Disease:

40
Heart, Kidney, Brain, Endothelial, Bone Marrow, Cardiac Myocytes, Eye

Publications for Hypertensive Heart Disease

Articles related to Hypertensive Heart Disease:

(show top 50) (show all 1605)
# Title Authors PMID Year
1
Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. 61 54
19887955 2009
2
Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. 54 61
19117407 2009
3
Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. 54 61
18086943 2008
4
Tiotropium, a novel muscarinic M3 receptor antagonist, improved symptoms of chronic obstructive pulmonary disease complicated by chronic heart failure. 54 61
17127817 2006
5
Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. 61 54
17143708 2006
6
Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. 54 61
16371224 2006
7
Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. 54 61
16043943 2005
8
Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. 54 61
15313958 2004
9
Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. 61 54
15093887 2004
10
Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. 54 61
15202614 2004
11
Peroxisome proliferator-activated receptor alpha and hypertensive heart disease. 61 54
15765888 2004
12
The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. 54 61
14597852 2003
13
Natriuretic peptide receptor A mediates renal sodium excretory responses to blood volume expansion. 61 54
12824076 2003
14
Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. 54 61
11569573 2001
15
Renin-angiotensin system inhibition improves coronary flow reserve in hypertension. 61 54
11392478 2001
16
Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. 54 61
10948081 2000
17
AT1 receptors: coronary flow and flow reserve. 54 61
10678287 2000
18
[Hypertensive heart disease with left ventricular diastolic dysfunction demonstrating restrictive hemodynamics: a case report]. 54 61
10396707 1999
19
Angiotensin converting enzyme inhibition by captopril influences cardiac work in healthy hearts. 61 54
9832171 1998
20
Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. 61 54
9405681 1997
21
Effects of moexiprilat on oestrogen-stimulated cardiac fibroblast growth. 54 61
9257913 1997
22
Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. 61 54
8890821 1996
23
Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. 54 61
8518539 1993
24
Texture analysis applied in T1 maps and extracellular volume obtained using cardiac MRI in the diagnosis of hypertrophic cardiomyopathy and hypertensive heart disease compared with normal controls. 61
33272531 2021
25
Hypertension, Prehypertension, Hypertensive Heart Disease, and Atrial Fibrillation. 61
33516406 2021
26
Oxygenation-Sensitive Cardiovascular Magnetic Resonance in Hypertensive Heart Disease With Left Ventricular Myocardial Hypertrophy and Non-Left Ventricular Myocardial Hypertrophy: Insight From Altered Mechanics and Cardiac BOLD Imaging. 61
33068066 2021
27
Cardiac magnetic resonance imaging features prognostic information in patients with suspected myocardial infarction with non-obstructed coronary arteries. 61
33309758 2021
28
Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. 61
33571994 2021
29
Estimation and determinants of direct medical costs of ischaemic heart disease, stroke and hypertensive heart disease: evidence from two major hospitals in Cameroon. 61
33579273 2021
30
Description of multimorbidity clusters of admitted patients in medical departments of a general hospital. 61
33547138 2021
31
The Effect of Antihypertensive Therapy on Left Ventricular Longitudinal Strain: Missing Part of the Puzzle. 61
32086702 2021
32
Worldwide Trends in Prevalence, Mortality, and Disability-Adjusted Life Years for Hypertensive Heart Disease From 1990 to 2017. 61
33583201 2021
33
Breastfeeding Challenges: ACOG Committee Opinion, Number 820. 61
33481531 2021
34
Breastfeeding Challenges: ACOG Committee Opinion Summary, Number 820. 61
33481526 2021
35
Left ventricular mass reduction and hypertrophy regression following renal artery revascularization: a meta-analysis. 61
32833917 2021
36
Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease. 61
32728989 2021
37
Prevalence of rheumatic heart disease in a major referral cardiology clinic in Ethiopia: A retrospective cross-sectional study. 61
33592020 2021
38
Artificial intelligence-based myocardial texture analysis in etiological differentiation of left ventricular hypertrophy. 61
33569410 2021
39
Maternal cardiovascular risk after hypertensive disorder of pregnancy. 61
32404402 2020
40
Orthogonal electrical cardioversion in atrial fibrillation refractory to biphasic shocks: a case series. 61
33442616 2020
41
Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect. 61
33224383 2020
42
A case report of an infiltrative cardiomyopathy in everyday practice: a specific cause that cannot be missed in the elderly. 61
33442642 2020
43
Physical Exercise Combined with Antihypertensive Drug Therapy on Left Ventricular Hypertrophy: Systematic Review and Meta-Analysis. 61
32776302 2020
44
Histological features of endomyocardial biopsies in patients undergoing hemodialysis: Comparison with dilated cardiomyopathy and hypertensive heart disease. 61
32721819 2020
45
Changes in the number of mast cells, expression of fibroblast growth factor-2 and extent of interstitial fibrosis in established and advanced hypertensive heart disease. 61
32603827 2020
46
Burden of cause-specific mortality attributable to heat and cold: A multicity time-series study in Jiangsu Province, China. 61
32745780 2020
47
The value of multimodality imaging in hypertensive heart disease. 61
33239554 2020
48
Cellular contribution to left and right atrial dysfunction in chronic arterial hypertension in pigs. 61
33251761 2020
49
Epidemiology of acutely decompensated systolic heart failure over the 2003-2013 decade in Douala General Hospital, Cameroon. 61
33225620 2020
50
Redox Regulation of Cardiac ASK1 (Apoptosis Signal-Regulating Kinase 1) Controls p38-MAPK (Mitogen-Activated Protein Kinase) and Orchestrates Cardiac Remodeling to Hypertension. 61
32903101 2020

Variations for Hypertensive Heart Disease

Expression for Hypertensive Heart Disease

Search GEO for disease gene expression data for Hypertensive Heart Disease.

Pathways for Hypertensive Heart Disease

Pathways related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 MMP9 MMP2 MMP1 FGF2 CTF1 CD36
2
Show member pathways
12.98 TIMP2 IGF1 FGF2 AGTR1 AGT ACE
3
Show member pathways
12.67 TIMP2 MMP9 MMP2 MMP1 FGF2 CASP3
4 12.58 MMP9 MMP2 MMP1 IGF1 FGF2 CASP3
5
Show member pathways
12.43 NPR1 NPPB NPPA AGTR1 AGT
6
Show member pathways
12.41 TPM1 NPR1 NPPB NPPA AGTR1 AGT
7 12.19 MMP9 MMP2 IGF1 FGF2 CASP3
8
Show member pathways
12.18 TPM1 IGF1 AGT ACE
9 12.12 MMP9 MMP2 MMP1 CASP3
10 11.87 MMP2 CASP3 AGTR1 AGT
11 11.86 MMP9 MMP2 MMP1 FGF2 CD36
12
Show member pathways
11.85 TIMP2 MMP9 MMP2 MMP1
13 11.76 TIMP2 MMP9 MMP2 FGF2
14 11.68 MMP9 MMP2 MMP1
15 11.63 MMP9 MMP2 CASP3
16
Show member pathways
11.63 NPPB NPPA IGF1 FGF2 CTF1 AGT
17 11.62 MMP9 MMP2 CASP3
18
Show member pathways
11.62 NR3C2 CYP11B2 AGTR1 AGT ACE
19 11.61 MMP9 IGF1 FGF2
20
Show member pathways
11.59 MMP9 MMP2 MMP1
21 11.56 MMP9 MMP2 IGF1 FGF2
22 11.39 NPR1 NPPA AGTR1 AGT ACE
23 11.36 TIMP2 MMP9 MMP1
24 11.29 MMP9 MMP2 MMP1
25 11.17 MMP9 MMP2 CD36 ACE
26 11.1 TIMP2 MMP9 FGF2
27 11.06 MMP9 MMP2 ACE
28 10.99 MMP2 MMP1 IGF1
29 10.81 TIMP2 MMP9 MMP2 MMP1 IGF1

GO Terms for Hypertensive Heart Disease

Cellular components related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TIMP2 NPPB NPPA MSTN MMP9 MMP2
2 collagen-containing extracellular matrix GO:0062023 9.63 TIMP2 NPPA MMP9 MMP2 ANXA5 AGT
3 extracellular matrix GO:0031012 9.56 TIMP2 MMP9 MMP2 MMP1
4 extracellular space GO:0005615 9.4 TIMP2 NPPB NPPA MSTN MMP9 MMP2

Biological processes related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.99 NPR1 NPPB CTF1 CD36 AGT
2 extracellular matrix organization GO:0030198 9.96 MMP9 MMP2 MMP1 FGF2
3 cellular protein metabolic process GO:0044267 9.95 NPPA MMP2 MMP1 IGF1
4 negative regulation of cell growth GO:0030308 9.88 NPR1 NPPB NPPA AGT
5 positive regulation of MAPK cascade GO:0043410 9.87 TIMP2 IGF1 FGF2 CD36
6 wound healing GO:0042060 9.85 TPM1 IGF1 FGF2 CASP3
7 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 IGF1 CD36 AGT
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 IGF1 FGF2 AGT
9 regulation of cardiac conduction GO:1903779 9.8 NPR1 NPPA AGT
10 extracellular matrix disassembly GO:0022617 9.8 TIMP2 MMP9 MMP2 MMP1
11 collagen catabolic process GO:0030574 9.79 MMP9 MMP2 MMP1
12 cellular response to reactive oxygen species GO:0034614 9.77 TPM1 MMP9 MMP2
13 positive regulation of reactive oxygen species metabolic process GO:2000379 9.73 CD36 AGTR1 AGT
14 regulation of vasoconstriction GO:0019229 9.7 AGTR1 AGT ACE
15 cytokine-mediated signaling pathway GO:0019221 9.7 MMP9 MMP2 MMP1 FGF2 CTF1 CD36
16 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.69 CD36 AGTR1 AGT
17 response to amyloid-beta GO:1904645 9.67 MMP9 MMP2
18 positive regulation of urine volume GO:0035810 9.67 NPR1 NPPB
19 negative regulation of systemic arterial blood pressure GO:0003085 9.66 NPPB NPPA
20 regulation of vascular permeability GO:0043114 9.65 NPR1 NPPB
21 positive regulation of renal sodium excretion GO:0035815 9.65 NPR1 NPPB AGT
22 regulation of blood pressure GO:0008217 9.65 NPR1 NPPB NPPA AGT ACE
23 positive regulation of cholesterol esterification GO:0010873 9.64 AGTR1 AGT
24 positive regulation of cGMP-mediated signaling GO:0010753 9.64 NPR1 NPPA
25 body fluid secretion GO:0007589 9.63 NPR1 NPPB
26 positive regulation of NAD(P)H oxidase activity GO:0033864 9.63 AGTR1 AGT
27 cellular response to UV-A GO:0071492 9.63 MMP9 MMP2 MMP1
28 regulation of blood vessel diameter GO:0097746 9.62 NPR1 NPPB AGTR1 ACE
29 regulation of renal sodium excretion GO:0035813 9.61 AGTR1 AGT
30 renin-angiotensin regulation of aldosterone production GO:0002018 9.61 AGTR1 AGT
31 cGMP biosynthetic process GO:0006182 9.61 NPR1 NPPB NPPA
32 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.58 AGTR1 AGT
33 receptor guanylyl cyclase signaling pathway GO:0007168 9.58 NPR1 NPPB NPPA
34 regulation of renal output by angiotensin GO:0002019 9.54 AGT ACE
35 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.54 AGTR1 AGT ACE
36 cGMP-mediated signaling GO:0019934 9.26 NPR1 NPPB NPPA CD36
37 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.02 MMP9 MMP2 IGF1 FGF2 AGT

Molecular functions related to Hypertensive Heart Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.88 TIMP2 NR3C2 MMP9 MMP2 MMP1 ACE
2 peptidase activity GO:0008233 9.83 MMP9 MMP2 MMP1 CASP3 ACE
3 metallopeptidase activity GO:0008237 9.62 MMP9 MMP2 MMP1 ACE
4 growth factor activity GO:0008083 9.56 MSTN IGF1 FGF2 AGT
5 hormone activity GO:0005179 9.46 NPPB NPPA IGF1 AGT
6 hormone receptor binding GO:0051427 9.37 NPPB NPPA
7 bradykinin receptor binding GO:0031711 8.96 AGTR1 ACE
8 endopeptidase activity GO:0004175 8.92 MMP9 MMP2 MMP1 ACE

Sources for Hypertensive Heart Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....